Daily Roundup

CYC.ASX FND.ASX RAC.ASX SWF.ASX LTR.ASX

Cyclopharm Secures 5-Year Agreement with US Veterans Administration

Cyclopharm Limited (ASX: CYC) has announced a significant milestone in its US expansion plans. The company has signed a 5-year Federal Supply Schedule agreement with the US Veterans Administration (VA), simplifying procurement and ensuring consistent supply of Technegas patient consumables across federal healthcare facilities.

This agreement streamlines the process for US federal agencies, including the 120 VA hospitals, the Department of Defense, and Public Health Service hospitals, to access Cyclopharm's Technegas technology. By eliminating the need for individual contracts, the deal enhances efficiency and strengthens Cyclopharm's partnership with the VA, underscoring the clinical value of Technegas for US veterans.

Cyclopharm CEO James McBrayer stated that securing this long-term contract is a major achievement, as it solidifies the company's presence in the lucrative US market and positions Technegas for continued growth within the federal healthcare system.

Findi Ltd Requests Trading Halt

Findi Ltd has requested a trading halt in its shares (ASX: FND) pending the release of an announcement regarding the positive impact of the Reserve Bank of India's increase in interchange rates. The trading halt will remain in place until the earlier of the market open on 18 March 2025 or when the announcement is made public.

Findi expects to inform the market of the benefits of the RBI's decision on its business before the market opens on 18 March. The trading halt will assist the company in managing its continuous disclosure obligations as it prepares to release this update.

Race Oncology Receives Ethics Approval for RC220 Phase 1 Trial

Race Oncology Ltd (ASX: RAC) has received approval from the Bellberry Human Research Ethics Committee to initiate a Phase 1 clinical trial of its lead asset, RC220, a reformulated version of bisantrene. The trial will assess the safety, tolerability, and pharmacokinetics of RC220 alone and in combination with doxorubicin in patients with solid tumors.

The open-label, multi-center study will be conducted in two stages. Stage 1 will focus on dose escalation of RC220, while Stage 2 will recruit patients to confirm the safety of the RC220-doxorubicin combination and explore potential cardioprotective, anticancer, and anti-aging effects.

Race expects most Australian sites to be activated in the first half of 2025, with Hong Kong and South Korean sites coming online in the third quarter.

Selfwealth Scheme Meeting Approved by Court

Selfwealth Ltd (ASX: SWF) has announced that the Federal Court has approved the convening of a shareholder meeting to vote on the proposed acquisition of Selfwealth by Syfe Pte Ltd. A Scheme Booklet providing details about the transaction will be distributed to shareholders ahead of the Scheme Meeting, scheduled for 22 April 2025.

The Selfwealth Directors unanimously recommend that shareholders vote in favor of the Scheme, in the absence of a superior proposal and subject to the Independent Expert's continued conclusion that the Scheme is in the best interests of Selfwealth shareholders.

Liontown Resources Reports Solid H1 FY25 Results

Liontown Resources Ltd (ASX: LTR) has delivered strong operational and financial results for the first half of the 2025 fiscal year. The company successfully commenced spodumene concentrate production at its Kathleen Valley project, achieving significant improvements in plant availability and lithia recovery.

Liontown recorded $100.4 million in revenue from the sale of 92,172 dry metric tons of spodumene concentrate at an average realized price of US$811 per dry metric ton. The company also reported positive EBITDA during the initial ramp-up phase, despite capitalizing $39 million in commissioning costs.

Looking ahead, Liontown is targeting spodumene concentrate production of around 200,000 dry metric tons in the second half of FY25, with a lithia recovery of approximately 65% and unit operating costs (FOB excluding sea freight and royalties) of around US$650 per dry metric ton.